# A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct05399654/  
OnCo record `nct05399654` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TAC-001 run by Tallac Therapeutics, of unknown status on the registry.

## Summary

A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05399654 by Tallac Therapeutics, with 72 participants planned, started 2022-06-28. Conditions recorded: Advanced or Metastatic Solid Tumors. Interventions recorded: TAC-001.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05399654
- Phase: 1/2
- Setting: A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
- Sponsor: Tallac Therapeutics
- Enrolled: 72

## Sources

- ClinicalTrials.gov NCT05399654: https://clinicaltrials.gov/study/NCT05399654

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [TAC-001](https://onco.cc/drugs/tac-001/)
- companies: [Tallac Therapeutics](https://onco.cc/companies/tallac-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05399654.json